Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom

Area of Science:

• Parasitology
• Drug Discovery
• Biochemistry

Background:

• Chagas disease, caused by Trypanosoma cruzi, affects millions globally with no effective cure.
• Current treatments fail to address chronic infections, leading to severe comorbidities and death.
• Antimicrobial peptides (AMPs) from invertebrates show potential for novel therapeutic development.

Purpose of the Study:

• To dissect the trypanocidal effects of M-PONTX-Dq3a fragments and substituted analogs.
• To improve peptide trypanocidal activity, bioavailability, and reduce production costs for Chagas disease treatment.
• To identify novel bio-therapeutic agents for chronic Chagas disease.

Main Methods:

• Isolation and characterization of M-PONTX-Dq3a from Dinoponera quadriceps ant venom.
• Synthesis and evaluation of M-PONTX-Dq3a peptide fragments and substituted analogs.
• In vitro testing of peptide activity against benznidazole-resistant Trypanosoma cruzi strains.

Main Results:

• Identified two smaller peptides, M-PONTX-Dq3a [1-15] and [Lys]3-M-PONTX-Dq3a [3-15], with potent trypanocidal activity.
• These fragments demonstrated comparable efficacy to the parent peptide against all three forms of T. cruzi.
• The identified peptides show promise for improved bioavailability and reduced production costs.

Conclusions:

• M-PONTX-Dq3a fragments represent promising candidates for novel Chagas disease bio-therapeutics.
• These findings open new therapeutic avenues for treating chronic Chagas disease.
• Further development could lead to effective treatments for millions affected by Chagas disease.